The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.60692/nd4q9-zpp63
Publication URI: https://gresis.osc.int//doi/10.60692/nd4q9-zpp63
Type: Other